• In January 2019, Grifols and Rigel entered into an exclusive license and supply agreement to commercialize fostamatinib disodium hexahydrate. Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey.

  • Fostamatinib is commercially available in the U.S. under the brand name TAVALISSE® (fostamatinib disodium hexahydrate) and is the first and only SYK inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

  • Rigel received a $30 million upfront cash payment, with the potential for $297.5 million in payments related to regulatory and commercial milestones, which includes a $20 million payment for EMA approval of fostamatinib for the treatment of chronic ITP.

  • Grifols will be responsible for commercializing fostamatinib in its licensed territories after EMA approval. The MAA was validated by the EMA in October 2018, and is currently under review.

*Please see the TAVALISSE full Prescribing Information at